Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/23895
Title: | Hydroxyurea for transfusion dependent β-thalassaemia: A randomized double-blind placebo-controlled clinical trial |
Authors: | Yasara, N. Wickramarathne, N. Silva, I. Hameed, N. Attanayaka, A.M.K.R. Jayasinghe, V.L. Gunathilaka, P.A.C.K. Wickramasinghe, N. Rodrigo, R. Perera, L Perera, P.S. Mettananda, K.C.D. Manamperi, A. Premawardhena, A. Mettananda, S. |
Keywords: | β-thalassaemia |
Issue Date: | 2021 |
Publisher: | Sri Lanka Medical Association |
Citation: | Sri Lanka Medical Association, 134th Anniversary International Medical Congress. 2021; 162 |
Abstract: | Introduction and objectives Hydroxyurea induces fetal haemoglobin in vitro however, its clinical usefulness in β-thalassaemia is unclear. Here, we aim to assess the efficacy and safety of oral hydroxyurea in patients with transfusion dependent β-thalassaemia. Methods A phase 3 randomized double-blind placebo-controlled clinical trial was conducted at Colombo North Teaching Hospital in 2019/20. Sixty patients with transfusion dependent β-thalassaemia were randomized into hydroxyurea (10-20mg/kg/day) or placebo groups. Transfused blood volume, pre-transfusion haemoglobin, fetal haemoglobin and adverse effects were monitored during 6-month treatment and post-treatment periods. The study was approved by the ethics committee of University of Kelaniya and registered in Sri Lanka Clinical Trials Registry (SLCTR/2018/024). Results Fifty-four (hydroxyurea-27; placebo-27) patients completed the trial. Mean pre-transfusion haemoglobin (8.2±0.8g/ dLvs8.0±0.88g/dL, p=0.43) and fetal haemoglobin levels (7.9±11.2%vs4.6±4.3%, p=0.17) were higher in hydroxyurea group compared to placebo. Also, transfused blood volume was lower in the hydroxyurea group (94±29ml/kgvs102±28ml/kg, p=0.34). However, none were statistically significant. Based on elevation of fetal haemoglobin (>1.5% from baseline), we identified 12/27 patients who respond well to hydroxyurea (hydroxyurea-responders). Hydroxyurea-responders required significantly lower blood volume (77±27ml/kg) compared to non-responders (108±24ml/kg, p<0.01) and placebo group (102±28ml/kg, p<0.05). HbE β-thalassaemia sub-type (p<0.01) and Xmn1 polymorphism of γ-globin gene (p<0.05) were significant predictors of response to hydroxyurea. No serious side effects due to hydroxyurea were reported. Conclusion Over 40% of patients with transfusion dependent β-thalassaemia- specifically those with HbE β-thalassaemia and Xmn1 polymorphism of γ-globin gene- responded to hydroxyurea and required 25% less blood compared to controls. No serious adverse effects were reported following hydroxyurea treatment. |
Description: | Poster Presentation Abstract, “Professional Excellence Towards Holistic Healthcare”, 134th Anniversary International Medical Congress, Sri Lanka Medical Association, 21st – 24th September 2021, Colombo, Sri Lanka |
URI: | http://repository.kln.ac.lk/handle/123456789/23895 |
Appears in Collections: | Conference Papers |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.